Erin K. Brenner - Jan 14, 2023 Form 4 Insider Report for Pear Therapeutics, Inc. (PEARQ)

Role
Chief Product Dev. Officer
Signature
/s/ Stacie S. Aarestad, Attorney-in-Fact
Stock symbol
PEARQ
Transactions as of
Jan 14, 2023
Transactions value $
$0
Form type
4
Date filed
1/18/2023, 05:42 PM
Previous filing
Dec 9, 2022
Next filing
Jan 24, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PEARQ Common Stock Options Exercise $0 +22K +73.33% $0.00 52K Jan 14, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PEARQ Restricted Stock Units Options Exercise $0 -22K -33% $0.00 44.7K Jan 14, 2023 Common Stock 22K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of PEAR common stock.
F2 The remaining restricted stock units shall vest and settle as to 33% of the shares on January 14, 2024 and 34% on January 14, 2025.